Citations

Clear

959 citation(s) found for "Service, F J".

Flap Complications Following Maxillectomy, Reconstructive Surgery, and Postoperative Proton Radiotherapy: A Cohort Study and Considerations for Risk Mitigation
Safavi, Amir H. , Yang, Fan , Wu, Yingzhi, Matros, Evan , Hespe, Geoffrey E. , Gelblum, Daphna Y. , Cohen, Marc A. , Shen, Brian, Sine, Kevin, Mah, Dennis , Lee, Nancy Y. , Gelblum, Daphna Y , Cohen, Marc A , Ganly, Ian , Hung, Tony K. W. , Wong, Richard J. , Han, Dong Soo

Mayo Clinic

Head & Neck | September 8, 2025 | Volume: 48 | Issue: 2 | Pages: 407-415

10.1002/hed.70040 | PMID 40916977 Get It

ABSTRACT Background Flap complications following maxillectomy, reconstruction, and adjuvant proton beam therapy (PBT) for primary maxillary and sinonasal malignancies are not well described. Methods This retrospective cohort study included consecutive patients treated between 2016 and 2023 from a single‐institutional database. Results Thirteen patients were identified with a median follow‐up of 26 months. No immediate post‐operative complications occurred, with a median time between surgery and PBT of 61 days. Nine patients (69.2%) had high‐risk postoperative pathology and required 66+ Gy(RBE), including five (38.5%) with gross disease receiving 70 Gy(RBE). Flap necrosis and fistulization occurred in three patients (23.1%) following PBT (median time from PBT to complication, 112 days). Higher flap mean and minimum dose, flap volume receiving at least 66 Gy[RBE], and minimum dose to 50% flap volume were associated with complications. Conclusions Careful patient selection and planning strategies should be considered to mitigate flap complication risk following adjuvant PBT for high‐risk post‐operative pathology.
Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy
Venkataraman, Shreyas , Deshmukh, Abhishek , Siontis, Konstantinos C. , Konecny, Thomas, Somers, Virend K., Karim, Shahid , Mansukhani, Meghna, Karim, Shahid, Chahal, C. Anwar A. , Mansukhani, Meghna P. , Khanji, Mohammed Y , Petersen, Steffen E. , Gersh, Bernard J. , Geske, Jeffrey B.

Mayo Clinic

JAMA Cardiology | September 3, 2025 | Volume: 10 | Issue: 10 | Pages: 1024

10.1001/jamacardio.2025.2877 | PMID 40900558 Get It

Importance Sleep disordered breathing (SDB) is a well-established contributor to cardiovascular morbidity, mediated by intermittent hypoxemia, autonomic dysregulation, and endothelial dysfunction. Patients with hypertrophic cardiomyopathy (HCM) may be especially at risk for SDB, but the clinical impact of SDB in this population remains unclear. Objective To define the prevalence and subtypes of SDB in HCM and examine their association with echocardiographic parameters and cardiac biomarker expression. Design, Setting, and Participants A prospective cohort study was conducted between April 18, 2018, and January 15, 2024, at a single tertiary referral center specializing in HCM care. Adults with HCM (left ventricular wall thickness ≥15 mm or pathogenic variants) were recruited from an institutional registry. Patients diagnosed with SDB or current pregnancy were excluded. Patients underwent polysomnography, with comparative assessment of echocardiographic, electrocardiographic, and biomarker indices. Observers were blinded to polysomnographic results. Data analysis was performed from April 11, 2024, to July 25, 2024. Exposures SDB classified via polysomnography using apnea-hypopnea index thresholds, with subtypes including obstructive sleep apnea and central sleep apnea and with event severity, hypoxemia, and sleep architecture disruption quantified. Main Outcomes and Measures Echocardiographic indices, cardiac biomarker expression, functional status, apnea-hypopnea index, and overnight hypoxemia. Results Among 154 patients (median [IQR] age, 60 [48-68] years; 102 [66.2%] male), 91 (59.1%) were diagnosed with SDB. Those with SDB, compared with those without SDB, had higher left ventricular mass index (median [IQR], 128 [107-161] vs 109 [96-134] g/m 2 ; P = .03), E/e′ ratio (median [IQR], 12.5 [10.0-15.0] vs 10.0 [8.3-14.5]; P = .04), and baseline troponin-T level (median [IQR], 0.013 [0.009-0.022] vs 0.011 [0.007-0.015] ng/mL [to convert to micrograms per liter, multiply by 1]; P = .04) and greater overnight troponin-T level increases (change in median [IQR], 0.0021 [−0.0029 to 0.0062] vs 0.0002 [−0.0022 to 0.0026] ng/mL; P = .02). New York Heart Association class II or III symptoms were more common in those with SDB (48 [52.7%] vs 17 [27.0%]; P = .005). Hypertension and diabetes were more prevalent among patients with SDB than without SDB (hypertension: 67 [73.6%] vs 36 [57.1%]; P = .03; diabetes: 14 [15.4%] vs 3 [4.8%]; P = .04), whereas rates of atrial fibrillation and prior myectomy did not differ significantly between groups. Conclusions and Relevance This study suggests that undiagnosed SDB is highly prevalent in patients with HCM and that SDB is associated with adverse myocardial remodeling, greater diastolic dysfunction, and elevated troponin-T levels, indicating subclinical myocardial injury. SDB may contribute to HCM pathophysiology and symptom burden, supporting the rationale for randomized clinical trials to determine the impact of treating SDB on symptoms and clinical outcomes in patients with HCM.
Genetic and Cellular Architecture of Breast Cancer Risk Across Ancestries
Zanti, Maria , Williams, Jacob , Jahagirdar, Om , Turcan, Alistair, Brandenburg, Jean‐Tristan , Li, Jingmei, Miranda, Patricio , Godbole, Devika , Zhang, Xiaomeng , Dorling, Leila , Dennis, Joe, John, Esther M. , Kushi, Lawrence H., Carvajal‐Carmona, Luis G. , Haiman, Christopher A. , Ziv, Elad , Easton, Douglas F. , Chanock, Stephen J., Chatterjee, Nilanjan , Kraft, Peter, Wong, Wendy S W , Zhu, Qianqian , Ahearn, Thomas U., Li, Jingmei , Zhang, Haoyu , John, Esther M , Li, Jingmei , Ziv, Elad , Li, James , Jia, Guochong , Hu, Qiang , Li, Yàn , Ho, Weang-Kee , Dias, Julie‐Alexia , Chen, Wenlong Carl , Boddicker, Nicholas , Wang, Ying , Martin, Alicia R. , Zhang, Yan , Torres-Mejı́a, Gabriela , Kushi, Lawrence H, Weitzel, Jeffrey N. , Neuhausen, Susan L. , Fejerman, Laura , Zheng, Wei , Huo, Dezheng , Chanock, Stephen Jacob , Chatterjee, Nilanjan , García‐Closas, Montserrat , Michailidou, Kyriaki , Zhang, Martin Jinye , Dutta, Diptavo , Ahearn, Thomas U.

Mayo Clinic

No container title available | August 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.20.25334075 | PMID 40909829 Get It

Abstract Background Breast cancer genome-wide association studies (GWAS) have identified more than 200 susceptibility loci, but most studies are dominated by European and East Asian populations. Methods We analyzed breast cancer GWAS summary statistics from African (AFR), East Asian (EAS), European (EUR), and Hispanic/Latina (H/L) samples (159,297 cases and 212,102 controls). We estimated logit-scale SNP-based heritability, polygenicity, and cross-ancestry genetic correlation, partitioned heritability across functional annotations, and integrated GWAS results with the Tabula Sapiens single-cell atlas using scDRS+. Results The logit-scale heritability of breast cancer ranged from ℎ 2 =0.47 (SE = 0.07) in EAS to AFR ℎ 2 =0.61 (SE = 0.10), with no significant differences across ancestries (p=0.63). The estimated number of susceptibility markers in a sparse normal-mixture effects model also varied from 4,446 (SE = 3,100) in EAS to 8,308 (SE = 2,751) in AFR, but differences were not significant across ancestries (p=0.55). Cross-sample genetic correlations varied, with the strongest correlation between EUR and EAS (𝜌 = 0.79, SE = 0.08) and weakest between AFR and H/L (𝜌 = 0.26, SE = 0.24). Regulatory annotations were enriched for breast cancer heritability across samples. Integration with single-cell expression profiles implicated ancestry-shared associations with innate immune, secretory epithelial, and stromal cell types. Conclusion These results indicate substantial cross-ancestry sharing of breast cancer polygenic architecture, highlight a consistent contribution of regulatory variation, and identify convergent cellular contexts that motivate functional follow-up and inform expectations for the transferability and attainable performance of common-variant risk prediction across populations.
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Mékinian, A. , Georgin‐Lavaille, Sophie, Savic, Sinisa , Koster, Matthew J. , Comont, Thibault , Heilblig, Mael, Aróstegui, Juan I. , Bosco, Annmarie , Cargo, Catherine , Cattaneo, Chiara , Chasset, François , Coelho, Henrique , Ducharme‐Bénard, Stéphanie , Frassi, Micol, Hakobyan, Yervand , Jurcuț, Ciprian , Kirino, Yohei , Kunimoto, Hiroyoshi , Madigan, Lauren M. , Moráis, Sara , Sockel, Katja , Patnaik, Mrinal M. , Regadas, Luísa, Robin, Marie , Rutgers, Abraham , Salvarani, Carlo , Sammel, Anthony M. , Sujobert, Pierre , Tomelleri, Alessandro , Vandergheynst, Frédéric , Vieira, Romana, Viswanatha, David S., Diral, Elisa , Terrier, Benjamin , Fenaux, Pierre, Grayson, Peter C. , Beck, David B. , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological, Mékinian, Arsène , Koster, Matthew J , Bourguiba, Rim , Campochiaro, Corrado , Crisafulli, Francesca , Gurnari, Carmelo , Jamilloux, Yvan , Kirino, Yohei , Marvisi, Chiara , Milchert, Marcin , Rutgers, Abraham , Salvarani, Carlo , Tomelleri, Alessandro , Urbanski, Geoffrey , Terrier, Benjamin , Grayson, Peter C , Beck, David B , Robin, Marie , Savic, Sinisa , Georgin‐Lavialle, Sophie , Ferrada, Marcela A. , Kosmider, Olivier , Calvo, Katherine R. , Campochiaro, Corrado , Faria, Raquel , Franceschini, Franco , Groarke, Emma M , Gurnari, Carmelo , Kulasekararaj, Austin , Mann, H. , Marvisi, Chiara , Milchert, Marcin , Muratore, Francesco , Nakajima, Hideaki , Seebach, Jörg Dieter , Więsik–Szewczyk, Ewa , Patel, Bhavisha A. , Fenaux, Pierre , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological

Mayo Clinic

Arthritis & Rheumatology | August 11, 2025 | Volume: 78 | Issue: 3 | Pages: 509-522

10.1002/art.43287 | PMID 40787890 Get It

Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. Methods Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. Results Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. Conclusion This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.
Desmosomal Versus Non-Desmosomal Arrhythmogenic Cardiomyopathies: A State-of-the-Art Review
Galanti, Kristian , Iezzi, Lorena , Rizzuto, M, Falco, D. de , Negri, G., Pham, Hoang Nhat , Mansour, Davide , Giansante, Roberta , Mazzocchetti, L, Gallina, Sabina , Mantini, Cesare , Ricci, Fabrizio , Nhat, Hoang , Ricci, Fabrizio , Falco, Daniele, Negri, Giada , Stuppia, Liborio , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

Cardiogenetics | August 4, 2025 | Volume: 15 | Issue: 3 | Pages: 22

10.3390/cardiogenetics15030022 Get It

Arrhythmogenic cardiomyopathies (ACMs) are a phenotypically and etiologically heterogeneous group of myocardial disorders characterized by fibrotic or fibro-fatty replacement of ventricular myocardium, electrical instability, and an elevated risk of sudden cardiac death. Initially identified as a right ventricular disease, ACMs are now recognized to include biventricular and left-dominant forms. Genetic causes account for a substantial proportion of cases and include desmosomal variants, non-desmosomal variants, and familial gene-elusive forms with no identifiable pathogenic mutation. Nongenetic etiologies, including post-inflammatory, autoimmune, and infiltrative mechanisms, may mimic the phenotype. In many patients, the disease remains idiopathic despite comprehensive evaluation. Cardiac magnetic resonance imaging has emerged as a key tool for identifying non-ischemic scar patterns and for distinguishing arrhythmogenic phenotypes from other cardiomyopathies. Emerging classifications propose the unifying concept of scarring cardiomyopathies based on shared structural substrates, although global consensus is evolving. Risk stratification remains challenging, particularly in patients without overt systolic dysfunction or identifiable genetic markers. Advances in tissue phenotyping, multi-omics, and artificial intelligence hold promise for improved prognostic assessment and individualized therapy.
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Lee, Eudocia Q. , Khasraw, Mustafa , Rahman, Rifaquat , Platten, Michael , Lim, Michael , Verhaak, Roel G.W. , Albert, Nathalie L. , Schiff, David , Ostrom, Quinn T. , Aldape, Kenneth , Batchelor, Tracy T. , Chiocca, E. Antonio, DeGroot, John, French, Pim J. , Hegi, Monika E. , Lassman, Andrew B. , Mellinghoff, Ingo K. , Minniti, Giuseppe, Taphoorn, Martin , Weiss, von Deimling, Tobias, Zadeh, Gelareh , Reardon, David A. , Chang, Susan M. , Short, Susan , Weller, Michael , Touat, Mehdi , Khasraw, Mustafa , Platten, Michael , Winkler, Frank , Verhaak, Roel Gw , Albert, Nathalie L , Tonn, Joerg-Christian , Barnholtz-Sloan, Jill S , Cloughesy, Timothy F , French, Pim J , Galanis, Evanthia , Galldiks, Norbert , Mellinghoff, Ingo K , Roth, Patrick , Sanson, Marc , Wick, Wolfgang , Reardon, David A , Short, Susan C , Ostrom, Quinn T , Wen, Patrick Yung , Horbinski, Craig , Huang, Raymond Y. , Ahluwalia, Manmeet S. , Barnholtz‐Sloan, Jill S. , Bindra, Ranjit S. , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Rhun, Émilie Le , Mehta, Minesh P. , Roth, Patrick , Sanson, Marc , Weiss, von Deimling, Tobias, Wick, Wolfgang , Bent, Martin J. van den , Preusser, Matthias

Mayo Clinic

Neuro-Oncology | July 22, 2025 | Volume: 27 | Issue: 11 | Pages: 2751-2788

10.1093/neuonc/noaf177 | PMID 40827022 Get It

Abstract Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody–drug conjugates will be reviewed, as well as the current challenges and future directions for research.
Titin-related familial dilated cardiomyopathy: factors associated with disease onset
Johnson, Renée , Fletcher, Robert A. , Peters, Stacey , Ohanian, Monique , Soka, Magdalena , Smolnikov, Andrei , Abihider, Katherine E, Ackerman, Michael J. , Ader, Flavie , Akhtar, Mohammed , Ashley, Euan A. , Austin, Rachel , Baas, Annette F., Blouin, Jean‐Louis , Brown, Emily E. , Cannie, Douglas , Correnti, Gemma, Ferro, Matteo Dal , Dellefave‐Castillo, Lisa , Dooijes, Dennis , Dybro, Anne M. , Demri, Youssef Ed, Hachmi, Mohamed El , Escobar-López, Luis , Foye, Sarah , Gigli, Marta , López, Esther González , Goudal, Adeline , Graw, Sharon , Guipponi, Michel, Haan, Eric , Haas, Jan , Hammersley, Daniel , Hansen, Frederikke , Hey, Thomas Morris , Houweling, Arjan C. , Ingrey, A., Jabbour, Andrew , Jansweijer, Joeri A. , Jongbloed, Jan D.H. , Keogh, Anne , Deprez, Ronald H. Lekanne , Macciocca, Ivan , Mansencal, Nicolas , Mansour, Julia, Martinez‐Veira, Cristina, Medo, Kristen , Merlo, Marco , Michalak, Ewa , Monserrat, Lorenzo , Mountain, Helen , Murphy, Anne M. , Murray, Brittney , Pachter, Nicholas , Palmyre, Aurélien , Pereira, Naveen L. , Picard, Kermshlise, Prasad, Sanjay , Proukhnitzky, Julie , Pruny, Jean-François, Réant, Patricia , Ronan, Anne , Semsarian, Christopher , Storm, Garrett , Thomson, Kate , Thompson, Tina , Wallis, Mathew , Flagship, Australian Genomics Cardiac, Adès, Lesley C., Alankarage, Dimithu, almog, Morgan, Al-Shinnag, Mohammad , Barnett, Chris , Bodek, Simon , Boggs, Kirsten, Bray, Alessandra , Brown, Jaye, Burns, Charlotte , Cao, Michelle, Carr, Will, Casauria, Sarah , Chalinor, Heather V., Chang, Yu‐Chen , Charitou, Theodosia , Collins, Felicity, Correnti, Gemma, Cox, Kathy, Das, Debjani , Fazio, Paul De, Elzen, Nicola Den, Devery, Sophie , Dobbins, Julia , Elbracht-Leong, Stefanie, Enríquez, A. Juanico, Fatkin, Diane , Fear, Vanessa S. , Fine, Miriam, Garza, Denisse , Gongolidis, Laura, Gray, Belinda , Greer, Cassie, Haan, Eric, Haas, Mathilda, Hanna, Bernadette , Hayward, Janette, Herrera, Carmen, Hill, Adam P. , Hollingsworth, Georgie, Hollway, Georgina E. , Horton, Ari , Ingles, Jodie, Isbister, Joanne , Jane-Pantaleo, Sarah, Kelly, Andrew , King‐Smith, Sarah L., Lassman, Timo, Lipton, Jonathon, MacIntyre, Paul, Madelli, Evanthia O. , Martin, Ellenore , Medi, C., Metke, Alejandro, Morrish, A., Morwood, Jim, Mowat, David , Ng, Chai‐Ann , Nowak, Natalie , Martinez, Noelia Nunez, O'Sullivan, S. S. , Overkov, Angela, Perrin, Mark J. , Perry, Matthew , Pflaumer, Andreas , Phillips, Peta, Phuong, Thuan, Pope-Couston, Rachel, Poplawski, Nicola K., Punni, Preeti, Rajagopalan, Sulekha , Regan, Matthew, Rogers, Jonathan, Ryan, Mark , Sandaradura, Sarah A. , Schönrock, Nicole, Scuffham, Paul , Sherburn, Isabella, Sherlock, Mary-Clare, Smerdon, Carla, Smith, Janine , Smyth, Renee, Sy, Raymond W. , Tang, Dotti, Taylor, Shelby , Tchan, Michel , Trainer, Alison, Trivedi, Gunjan, Spaendonck‐Zwarts, Karin van , Vandenberg, Jamie I. , Verma, Kunal , Vidgen, Miranda E. , Vohra, Jitendra K. , Waddel-Smith, Kathryn, Weintraub, Robert G, Worgan, Lisa , Wornham, Linda, Wu, Kathy H. C. , Yeates, Laura , Zentner, Dominica, Arnott, Clare , Fokstuen, Siv , Meder, Benjamin , Giudicessi, John R. , Parikh, Victoria N. , Ware, James S. , Rooryck, Caroline , Lakdawala, Neal K. , Elliott, Perry , Charron, Philippe , Peña‐Peña, María Luisa, Mogensen, Jens , Rasmussen, Torsten B. , Seidman, Jonathan G. , Seidman, Christine E. , Riele, Anneline S.J.M. te , Pinto, Yigal M. , Christiaans, Imke , Fatkin, Diane, Gray, Belinda , Akhtar, Mohammed M , Amin, Ahmad S , Ashley, Euan A , Atherton, John J , Austin, Rachel , Baas, Annette F , Bagnall, Richard D , Ross, Samantha Barratt , Blouin, Jean-Louis , Brown, Emily E , Bundgaard, Henning , Cannie, Douglas , Chmielewski, Przemyslaw , Crespo-Leiro, Maria Generosa , Dal Ferro, Matteo , Dellefave-Castillo, Lisa M , Dominguez, Fernando , Dybro, Anne M , Ed Demri, Youssef , El Hachmi, Mohamed , Escobar-Lopez, Luis , Foye, Sarah Jajesnica , Franaszczyk, Maria , Gigli, Marta , Goudal, Adeline , Graw, Sharon , Guipponi, Michel , Haan, Eric , Hammersley, Daniel J , Hansen, Frederikke G , Hayward, Chris , Hey, Thomas Morris , Ho, Carolyn Y , Houweling, Arjan C , Jabbour, Andrew , Jansweijer, Joeri A , Jongbloed, Jan D H , Keogh, Anne M , Larrañaga-Moreira, Jose M , Lekanne Deprez, Ronald H , Macciocca, Ivan , Macdonald, Peter S , McDonough, Barbara , McGaughran, Julie , Medo, Kristen , Michalak, Ewa , Monserrat, Lorenzo , Mountain, Helen , Muller, Steven A , Murphy, Anne M , Oates, Emily C , Ormondroyd, Elizabeth , Pachter, Nicholas , Palmyre, Aurélien , Pereira, Naveen L , Proukhnitzky, Julie , Reant, Patricia , Richard, Pascale , Ronan, Anne , Sedaghat-Hamedani, Farbod , Semsarian, Christopher , Storm, Garrett , Stroeks, Sophie , Taylor, Matthew R G , Thomson, Kate , Thompson, Tina , van Tintelen, J Peter , Vissing, Christoffer Rasmus , Waddell-Smith, Kathryn E , Wallis, Mathew , Marian, Ali J , Fokstuen, Siv , Giudicessi, J R , Parikh, Victoria N , Piriou, Nicolas , Rooryck, Caroline , Lakdawala, Neal K , Mestroni, Luisa , van Spaendonck-Zwarts, Karin Y , Garcia-Pavia, Pablo , Peña-Peña, Maria Luisa , Christensen, Alex Hoerby , Bilińska, Zofia T , Rasmussen, Torsten B , Seidman, Jonathan G , Seidman, Christine E , Te Riele, Anneline S J M , Ware, James S , Gray, Belinda , Vandenberg, Jamie I , Fletcher, Robert A , Amin, Ahmad S. , Bundgaard, Henning , Crespo‐Leiro, María G. , Domínguez, Fernándo , Heymans, Stéphane , Ho, Carolyn Y. , Ingles, Jodie , James, Paul A. , McGaughran, Julie , Paldino, Alessia , Poplawski, Nicola Kazia , Prasad, Sanjay K , Syrris, Petros , Taylor, Matthew R.G. , Tintelen, J. Peter van , Zentner, Dominica , Flagship, Australian Genomics Cardiac, Barnett, Chris, Blue, Gillian M. , Bogwitz, Michael R. , Boughtwood, Tiffany F. , Brion, Marie‐Jo , Bryson‐Richardson, Robert J. , Burnett, Leslie , Chapman, Gavin , Chong, Belinda , Correnti, Gemma, Cox, Kathy, Cunningham, Fiona, Davis, Jason A. , Davis, Andrew M. , Silva, M. De , Dunwoodie, Sally L. , Dwyer, Nathan , Elliott, David A. , Enriquez, Annabel, Finlay, Keri , Giannoulatou, Eleni , Greer, Cassie, Harvey, Richard Paul , Herrera, Carmen, Hill, Adam, Howting, Denise A. , Jackson, Matilda R. , Johnson, Renee, Kirk, Edwin Philip , Kummerfeld, Sarah , Lunke, Sebastian , MacIntyre, Paul, Mallawaarachchi, Amali C. , Mathew, Jacob , Mattiske, Tessa , McLean, Alison K. , McNamara, James W. , Milnes, Di , Milward, Michael, O'Sullivan, Sinead, Patel, Chirag , Quinn, Michael C. , Raju, Hariharan , Rath, Emma M. , Regan, Matthew, Ryan, Mark, Singer, Emma S. , Stark, Zornitza , Taylor, Jessica, Thorpe, Jordan , Trivedi, Gunjan , Valente, Giulia , Wilson, Meredith , Winlaw, David Scott , Zentner, Dominica, Oh, Jae Won , James, Cynthia A. , Villa, Roberto Barriales , Wahbi, Karim , Mestroni, Luisa , Sinagra, Gianfranco , Watkins, Hugh , McNally, Elizabeth M. , Charron, Philippe , Verdonschot, Job A.J.

Mayo Clinic

European Heart Journal | July 18, 2025 | Volume: 46 | Issue: 48 | Pages: 5240-5257

10.1093/eurheartj/ehaf380 | PMID 40796136 Get It

Abstract Background and Aims Truncating variants in the TTN gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) but also occur as incidental findings in the general population. This study investigated factors associated with the clinical manifestation of TTNtv. Methods An international multicentre retrospective observational study was performed in families with TTNtv-related DCM. Shared frailty models were used to estimate associations of variant characteristics with lifetime risk of DCM, and logistic regression to estimate odds ratios (ORs) for individual-level clinical risk factor profiles (cardiac conditions, cardiovascular comorbidities, lifestyle) and DCM. Results A total of 3158 subjects in 1043 families with TTNtv-related DCM were studied. TTNtv-positive subjects were 21-fold more likely to develop DCM [OR, 21.21; 95% confidence interval (CI), 14.80–30.39]. Disease onset was earlier in males, but was similar for TTNtv of different types and locations. The presence of clinical risk factors was associated with earlier DCM onset (OR, 3.41; 95% CI, 2.06–5.64), with a prior history of atrial fibrillation having a two-fold increased odds of DCM (OR, 2.05; 95% CI, 1.27–3.32). The prevalence of clinical risk factors increased with age; however, the strength of the DCM association was greatest for young-onset (<30 years) disease (OR, 4.75; 95% CI, 2.35–9.60). Administration of beta-adrenergic receptor or renin-angiotensin system-blocking drugs prior to overt DCM was associated with 87% reduced odds of DCM (OR, .13; 95% CI, .08–.23). Conclusions Disease onset in TTNtv-associated familial DCM is dependent on individual patient context and is potentially modifiable by risk factor management and prophylactic therapeutic intervention.
Left ventricular wall thickness heterogeneity improves cardiovascular disease diagnosis and prognosis: a UK Biobank cardiovascular magnetic resonance cohort study
Hesse, Kerrick , Khanji, Mohammed Y , Chahal, C. Anwar A. , Petersen, Steffen E. , Aung, Nay , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Petersen, Steffen E , Aung, Nay

Mayo Clinic

European Heart Journal - Imaging Methods and Practice | July 18, 2025 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/ehjimp/qyaf092 | PMID 40740418 Get It

Abstract Aims Left ventricular hypertrophy (LVH) regionality carries diagnostic and prognostic importance. Mean absolute deviation of maximum segmental wall thickness (MadWT) is a novel left ventricular wall thickness (LVWT) heterogeneity biomarker from cardiovascular magnetic resonance imaging (CMR). Objectives To compare MadWT to indexed LV mass (LVMi), maximum (MaxWT) and mean (MeanWT) wall thickness to predict incident cardiovascular disease (CVD) and differentiate physiological from pathological LVH in highly physically active individuals. Methods and results Deep learning-assisted analysis of 44 930 UK Biobank CMR scans produced WT indices. Cox regression modelled major adverse cardiovascular events (MACE), heart failure (HF), arrhythmia, and all-cause death against LVWT indices. In the top 1% most physically active biomarker differences between propensity score matched hypertensive and non-hypertensive groups were compared. Over median (Q1, Q3) follow-up of 5.7 (4.9, 7.1) years, MadWT, MaxWT, MeanWT, and LVMi were associated with greater risk of MACE, HF, arrhythmia (P < 0.05), but not all-cause death (P > 0.05). After adjusting for CMR biomarkers, including LVMi, MadWT remained independently prognostic of the greatest number of endpoints, including MACE, HF, and arrhythmia [HR 1.13 (1.04–1.23); HR 1.15 (1.01–1.32); and HR 1.26 (1.18–1.35) respectively]. In the top 1% most physically active by three metrics, MadWT was the only significantly different biomarker between hypertensive and non-hypertensive participants (P < 0.05). Conclusion MadWT is important prognostically beyond LV mass and may be useful when differentiating physiological from hypertensive LVH. Although findings require confirmation in athletic and diseased cohorts, MadWT is readily translatable to deep learning-assisted clinical CMR reporting, especially in early unexplained LVH.
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Borgeaud, Maxime , Olivier, Timothée , Bar, Jair , Saw, Stephanie P.L. , Parikh, Kaushal , Banna, Giuseppe Luigi , Vito, Claudio De , Feldman, Jill , Le, Xiuning , Addeo, Alfredo , Saw, Stephanie Pei Li , De Vito, Claudio , Addeo, Alfredo , Olivier, Timothée , Feldman, Jill

Mayo Clinic

CA: A Cancer Journal for Clinicians | July 17, 2025 | Volume: 75 | Issue: 5 | Pages: 387-409

10.3322/caac.70024 | PMID 40673977 Get It

AbstractThe discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped the treatment paradigm for EGFR‐mutant non‐small cell lung cancer. TKIs are now incorporated into the management of early stage and locally advanced disease, and phase 3 trials have explored combination strategies in metastatic settings. Although these intensified approaches improve progression‐free survival, they come with increased toxicity and higher costs, underscoring the need for precise patient selection to maximize benefit. Emerging data on biomarkers, such as co‐mutations and circulating tumor DNA, show promise for refining treatment decisions. In addition, significant progress in understanding resistance mechanisms to EGFR TKIs has broadened therapeutic options. This review provides a comprehensive overview of the current landscape of EGFR‐mutant nonsmall cell lung cancer, highlighting recent breakthroughs and discussing strategies to optimize treatment based on the latest evidence.
Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic
Droste, Marvin , Puhka, Maija , Ng, Monica Suet Ying , Álvarez‐Llamas, Gloria , Borràs, Francesc E. , Büscher, Anja , Bussolati, Benedetta , Dear, James W. , Hoorn, Ewout J. , Lenassi, Metka , Pink, Desmond , Tiwari, Swasti , Vizio, Dolores Di , Zarovni, Nataša , Martens‐Uzunova, Elena S. , Erdbrügger, Uta , Ng, Monica S Y , Alvarez-Llamas, Gloria , Borràs, Francesc E , Bussolati, Benedetta , Falcón-Perez, Juan Manual , Lenassi, Metka , Lucien, Fabrice , Tertel, Tobias , Martens-Uzunova, Elena S , Royen, Martin E. van , Blijdorp, Charles J. , Falcón‐Pérez, Juan Manuel , Giebel, Bernd , Grange, Cristina , Leivo, Janne , Llorente, Alicia , Lucien, Fabrice , Mertens, Inge , Mischak, Harald , Yuen, Peter S.T. , Jenster, Guido , Burger, Dylan

Mayo Clinic

Journal of Extracellular Vesicles | July 17, 2025 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/jev2.70120 | PMID 40673839 Get It

ABSTRACT Despite remarkable interest in the biomarker potential of urinary extracellular vesicles (uEVs) and the identification of numerous promising candidates, their clinical translation still presents multiple challenges. The opportunities for successful translation are obvious, yet the main roadblocks on the way have hardly been systematically considered and more coordinated approaches are needed to overcome them. In the present review article, we have identified the most relevant roadblocks of clinical translation of urinary EV‐based biomarkers and discuss possible solutions to overcome them. These roadblocks are categorized as fundamental and technical but also related to development of novel biomarker assays and clinical acceptance. In addition, hurdles within the regulatory approval process are discussed. It is clear that various roadblocks to clinical translation of urinary EV biomarkers exist; however, they are addressable by promoting rigor and reproducibility as well as collaboration between basic and clinical scientists, clinicians, industry and regulatory bodies. Moreover, knowledge of obstacles for assay development and regulatory requirements should already be considered when developing a new biomarker to maximize the chance of successful translation. This review presents not only a status quo, but also a roadmap for the further development of the field.